Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global
innovator in drug delivery platforms, today announced that it has reached a new
definitive agreement to provide its patented DehydraTECH(TM) technology to
Cannadips’ cannabis products, both in its current California market and across
the United States. According to the update, Lexaria’s DehydraTECH fast-acting,
high-absorption technology is perfectly suited to improve consumer satisfaction
and the dipping experience. Terpene-rich multi spectrum oils are base
ingredients of Cannadips THC, and DehydraTECH is able to reduce throat
irritation normally associated with some terpenes. Inferior products utilize
less efficacious cannabis isolate without terpenes that lack the entourage
effect derived from multi-spectrum oils in an attempt to get around this
problem. “Lexaria is building a stronger relationship with the Cannadips brand
and applying DehydraTECH to Cannadips cannabis represents our latest advance,”
Lexaria Bioscience CEO Chris Bunka stated in the news release. “Our DehydraTECH
technology empowers a scalable supply chain across state lines for our cannabis
brand licensees. We are excited that Cannadips is interested in activating the
Lexaria technology in additional key state markets that are either recreational
or medical cannabis states, while preserving the brand rights as states come
online through regulation.”
To view the full press release, visit http://ibn.fm/jj3JQ
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery
platforms. The company’s patented DehydraTECH drug-delivery technology changes
the way active pharmaceutical ingredients enter the bloodstream, promoting
healthier ingestion methods, lower overall dosing and higher effectiveness for
lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time
of onset and masks unwanted tastes for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to
multiple companies in the cannabis industry for use in cannabinoid beverages,
edibles and oral products, as well as to a world-leading tobacco producer for
the development of smokeless, oral-based nicotine products. Lexaria operates a
licensed, in-house research laboratory and holds a robust intellectual property
portfolio with 16 patents granted and over 60 patents pending worldwide. For
more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
